What is IFM Therapeutics?
IFM Therapeutics is a biopharmaceutical company dedicated to improving patient outcomes for those suffering from inflammation-driven diseases and cancer. The company specializes in creating first-in-class small molecules designed to modulate immune responses. With a robust pipeline of drug candidates progressing from discovery through clinical studies, IFM Therapeutics is addressing critical unmet medical needs. Their focus on the innate immune system positions them at the forefront of innovative therapeutic development in oncology and immunology.
How much funding has IFM Therapeutics raised?
IFM Therapeutics has raised a total of $82.5M across 2 funding rounds:
Series A
$27M
Unspecified
$55.5M
Series A (2016): $27M with participation from Atlas Venture, Novartis, and Abingworth
Unspecified (2019): $55.5M led by Abingworth, Omega Funds, and Atlas Venture
Key Investors in IFM Therapeutics
Abingworth
Abingworth is a leading transatlantic life sciences investment firm that provides capital and expertise to build world-class companies. They focus on seed, early-stage, development stage, and clinical co-development investments in therapeutic areas.
Omega Funds
Omega Funds is a venture capital firm with a primary investment focus on drug discovery and development companies. They have extensive experience in healthcare investing across Europe and the US.
Atlas Venture
Atlas Venture is an early-stage venture capital firm dedicated to creating and building breakthrough biotechnology companies. They partner with entrepreneurs to launch and grow innovative biotech startups, transforming scientific discoveries into life-changing medicines.
What's next for IFM Therapeutics?
The substantial enterprise-level funding and recent strategic investment indicate that IFM Therapeutics is poised for significant expansion and advancement of its drug development programs. This capital infusion will likely accelerate the progression of its promising candidates through clinical trials, potentially leading to new treatment options for patients. The company's strategic focus on the innate immune system suggests a continued emphasis on pioneering therapies in oncology and inflammatory diseases, aiming to solidify its position as a leader in the biopharmaceutical sector.
See full IFM Therapeutics company page
